Locus Announces Focus on Drug Discovery Collaboration Business, Branded as Ansaris
News Nov 09, 2009
Locus Pharmaceuticals has announced that in conjunction with a transformation to a drug discovery collaboration business model, it has created a new division, Ansaris, which will include most of its operations and personnel.
Ansaris was formed to leverage the strengths and fully realize the value of Locus’ drug discovery computational platform and 10 years’ experience in integrated drug design, discovery, and development. Ansaris establishes collaborations and partnerships with companies seeking innovative solutions to drug design challenges.
"We adopted the name Ansaris to symbolize our differentiated approach to drug discovery, leveraging our demonstrated expertise in computational chemistry, medicinal chemistry, and our unique fragment-based drug discovery technology platform,” said Joan Lau, President of Ansaris.
“The strength of the Ansaris discovery process lies not just with the technology, but also the integrated drug design team approach, uniquely customized for each project. We have effectively utilized our capabilities to deliver novel chemotypes for challenging targets for our internal pipeline, and now we will direct our successful discovery model toward delivering innovative preclinical candidates for our collaboration partners.”
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
Bumblebee Threats Tested in 'Virtual Safe Space'News
The many threats facing bumblebees can be tested using a “virtual safe space” created by scientists at the University of Exeter. Bumble-BEEHAVE provides a computer simulation of how colonies will develop and react to multiple factors including pesticides, parasites and habitat loss.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE